What is MabPlex International?
Founded in 2013, MabPlex International operates as a fully integrated CDMO, providing end-to-end solutions for global pharmaceutical developers. The company maintains a significant physical presence with R&D and production facilities spanning over 60,000 square meters across Yantai, Shanghai, and San Diego. Its technical infrastructure includes specialized production lines for monoclonal antibodies (mAb) and antibody-drug conjugates (ADC).
The firm's market position is defined by its ability to streamline the drug development lifecycle, from initial research to commercial-scale manufacturing. With a workforce exceeding 400 professionals, MabPlex has successfully supported over 40 pharmaceutical partners, facilitating more than 12 Investigational New Drug (IND) approvals across major regulatory bodies, including the FDA, TGA, and NMPA. This track record establishes the company as a vital link in the global biopharma supply chain.
How much funding has MabPlex International raised?
MabPlex International has raised a total of $59.1M across 1 funding round:
Series A
$59.1M
Series A (2019): $59.1M with participation from State Development & Investment Corporation
Key Investors in MabPlex International
State Development & Investment Corporation
A prominent state-owned investment firm based in China that focuses on long-term capital deployment across infrastructure, energy, and strategic industrial sectors.
What's next for MabPlex International?
Looking ahead, the strategic deployment of the recent capital will likely focus on scaling production capacity and deepening the company's expertise in complex biologics. As the demand for outsourced manufacturing services continues to rise, MabPlex is poised to leverage its existing infrastructure to capture additional market share in the ADC and mAb sectors.
The company's focus remains on optimizing clinical trial timelines and supporting the successful market launch of innovative therapies. By maintaining its commitment to regulatory excellence and technical precision, MabPlex is set to remain a key partner for developers navigating the increasingly complex landscape of modern drug development.
